Key Takeaways
- Shares of HIMS climbed as much as 13% following an FDA advisory committee’s 8-6 decision to support adding BPC-157 to the 503A Bulks List
- This decision enables state-licensed compounding pharmacies to manufacture BPC-157, creating a potential new business opportunity for Hims
- The favorable vote defied market expectations — prior FDA documentation had expressed safety reservations and suggested possible rejection
- Citi boosted its price target from $28 to $35 while noting that upside potential may be constrained before the August 10 earnings announcement
- Canaccord Genuity maintained its Buy recommendation with a $40 target, highlighting the peptide decision as supportive of its investment case
Shares of Hims & Hers Health climbed as high as 13% during Thursday’s session following a favorable FDA advisory committee decision regarding BPC-157, a widely-used peptide compound. The stock hovered near $32.75, pushing the telehealth company’s market valuation to approximately $7.6 billion.
Hims & Hers Health, Inc., HIMS
The FDA’s Pharmacy Compounding Advisory Committee delivered an 8-6 recommendation, with one member abstaining, to include BPC-157 on the 503A Bulks List. This classification permits state-regulated compounding pharmacies to create customized formulations of the peptide for individual patients.
The decision came as a surprise to market participants. Pre-meeting FDA briefing documents had highlighted potential safety issues and appeared to signal a likely negative outcome.
This marked the initial decision in a series of seven peptide evaluations spanning Thursday and Friday. The panel also delivered an 8-6 favorable recommendation for KPV, another peptide compound seeking similar classification.
The committee’s stance contradicted the position of FDA staff reviewers, who had previously recommended rejecting all seven substances under consideration during the meeting.
Implications for Hims & Hers
The advisory panel’s decision could unlock a fresh revenue opportunity for Hims. The telehealth platform maintains an extensive wellness customer base, and consumer interest in peptides such as BPC-157 has accelerated substantially.
Earlier in 2025, Hims purchased a peptide production facility in California, establishing internal manufacturing capabilities for these compounds. The company had postponed product launches while awaiting regulatory clarity from the FDA.
Canaccord Genuity maintained its Buy recommendation alongside a $40 price target, characterizing the committee’s decision as validation of the peptide reclassification investment thesis. The firm highlighted the potential for Hims to access a substantial addressable market opportunity.
Canaccord analysts further observed that HIMS shares outpaced major market indexes by several hundred basis points following the advisory committee decisions.
Analyst Perspectives Diverge
Not all analysts share the same enthusiasm. Citi’s Daniel Grosslight increased his price objective from $28 to $35 but cautioned that investor expectations appear elevated entering the company’s August 10 earnings release.
Grosslight expressed concerns about limited near-term appreciation potential, especially when excluding contributions from the Eucalyptus acquisition. He also identified elevated customer churn and a transition toward monthly subscription shipping as potential headwinds for revenue expansion.
Truist Securities maintained its Hold stance with a $23 price objective, emphasizing ongoing regulatory ambiguity. BofA Securities lifted its target to $37 while keeping a Neutral rating, expressing concern about customer retention rates among new oral Wegovy subscribers.
The Street’s consensus rating stands at Moderate Buy — comprising four Buy ratings and eight Hold ratings issued over the past three months. The average analyst price target of $30.14 suggests approximately 8% downside from current trading levels.
In separate news, the company announced that Chief Accounting Officer Irene Becklund will depart in October 2026. CFO Yemi Okupe will assume the responsibilities during the search for a permanent replacement.
Annual EPS projections stand at $0.39, with Wall Street anticipating that Hims could surpass Q2 2026 revenue expectations when results are released on August 10.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
